EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma

Jun-Hao Mei, Kai Zhang, Ying Zhang, Zhen Li, Nai-Jian Ge, Xue Han, Sui-Xing Zhong, Xiu-Ping Zhang, Ping-Ping Wu, Wei-Fu Lv, Jun Wu, Jian-Xiong Wu und 10 weitere

JHEP Reports · 2026-11 · 8 (11) · 102004

DOI: 10.1016/j.jhepr.2026.102004 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JHEP Reports, 2026-11. Verfasst von Jun-Hao Mei und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center of Interventional Radiology & Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radio…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Immunotherapy, Machine Learning. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China, Jiangsu Provincial Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Immunochemotherapy (IO-chemo) has become standard care for patients with unresectable intrahepatic cholangiocarcinoma (iCCA), but the benefit of adding IO varies greatly among individuals. We sought to develop a system to identify patients most likely to benefit from this treatment based on individualized treatment effect (ITE) estimation. METHODS: This study included patients with unresectable iCCA who underwent either IO-chemo or chemotherapy alone (chemo). Patients were enrolled from three discovery and seven external validation centers. Target trial emulation was used to obtain unbiased average treatment effect estimation, and a causal machine learning model was used to estimate heterogeneous treatment effects for IO-chemo. Based on predicted ITE, patients were stratified into high-benefit, no-to-moderate-benefit, and negative-benefit groups, with overall survival used as the primary end point. RESULTS: The discovery cohort included 1,485 patients; the external validation cohort included 562 patients. In the high-benefit group, compared with chemo, the hazard ratio (HR) for IO-chemo was 0.39 (95% CI 0.30-0.52; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsCholangiocarcinomaImmunotherapyMachine LearningPrecision MedicineAgedFemaleHumansMaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

Clinical decision supportComparative effectivenessCounterfactual inferencePrecision oncologyReal-world evidence

Autor:innen und Institutionen

  • Center of Interventional Radiology & Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital…
  • Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Intervention, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Yunnan Provincial Key Laboratory of Software Engineering, School of…
  • Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National Major Science and Technology Projects of China
  • Jiangsu Provincial Medical Center
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Mei, J. H., Zhang, K., Zhang, Y., Li, Z., Ge, N. J., Han, X., Zhong, S. X., Zhang, X. P., Wu, P. P., Lv, W. F., Wu, J., Wu, J. X., Wang, C., Yan, H., Huang, T., Liu, J., Jia, K. Z., Liu, Y., Guo, J. H., …, & Lu, J. (2026). Machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma. JHEP Reports, 8(11), 102004. https://doi.org/10.1016/j.jhepr.2026.102004

Vancouver

Mei JH, Zhang K, Zhang Y, Li Z, Ge NJ, Han X, et al. Machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma. JHEP Reports. 2026;8(11):102004. doi:10.1016/j.jhepr.2026.102004

BibTeX
@article{Mei2026,
  author = {Mei, Jun-Hao and Zhang, Kai and Zhang, Ying and Li, Zhen and Ge, Nai-Jian and Han, Xue and Zhong, Sui-Xing and Zhang, Xiu-Ping and Wu, Ping-Ping and Lv, Wei-Fu and Wu, Jun and Wu, Jian-Xiong and Wang, Chao and Yan, Hui and Huang, Tian and Liu, Jie and Jia, Kai-Zhi and Liu, Yue and Guo, Jin-He and Liu, Rong and Teng, Gao-Jun and Lu, Jian},
  title = {Machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma},
  journal = {JHEP Reports},
  year = {2026},
  volume = {8},
  number = {11},
  pages = {102004},
  doi = {10.1016/j.jhepr.2026.102004}
}
Kostenlos starten →